The first generation product, mycoplasma tissue culture test, was popularized in the United States.
2. The initial public offering (IPO) was completed in 1987, and the financing was16.2 million USD.
3. 1988 officially launched PACE? Detection reagent, which is the first generation of inspection equipment for two epidemic sexually transmitted diseases, CT and GC.
4. 1989 obtained the first American patent seal of ribosomal ribonucleic acid (rRNA) detection method, which is also the basis of Gen-Probe.
Approved by FDA to sell the first batch of four AccuProbe culture certification detection reagents.
5. 1994 launched four products in the United States: direct detection reagent for streptococcus a (GASDIRECT? ), CT and GC PACE? 2. Combined detection reagent, CT probe competition confirmation detection reagent and GC probe competition confirmation detection reagent.
7. 1995 proprietary DNA sequence amplification technology was patented in the United States, and TMA (transcription-mediated amplification technology) was introduced.
8. 1996 officially launched the amplified Mycobacterium tuberculosis complex nucleic acid detection reagent (TMA hybridization method) in the United States? ; The first FDA-approved nucleic acid amplification technique for detecting Mycobacterium tuberculosis.
9.200 1 FDA approves the sale of APTIMAbo 2? Determination.
This product is the second generation of nucleic acid amplification and determination. Through swab and urine sample, CT and GC can achieve the same detection effect.
10, 2002 FDA approved PROCLEIX developed by Gen-Probe? The reagent is used to simultaneously detect human immunodeficiency virus 1 (HIV- 1) and hepatitis C virus (HCV) in blood bank.
Officially launched DTS? 800 system, applied to APTIMA bo 2 In the reagent, automatic treatment is carried out.
1 1, acquired MLT company in 2003.
The technology developed by the company is the basis of gene probe chemiluminescence hybridization protection analysis (HPA) detection technology.
The FDA approved the use of fully automatic TIGRIS developed by Gen-Probe. DTS？ Systematically detect sexually transmitted diseases.
Approve TIGRIS system to run APTIMA COMBO 2? Reagent.
12005 FDA approved APTIMA? The reagent has been approved for marketing and used to detect gonococcus (GC).
Awarded the U.S. Patent Medal No.6890742, which claims to include the automatic process of isolating and amplifying the target DNA sequence in a closed system.
Grant us a listing license to use APTIMA bo 2? Cytyc's ThinPrep has been tested? Chlamydia trachomatis and Neisseria gonorrhoeae in liquid papilloma samples collected and processed by 2000 system.
President Bush awarded the 2004 US National Science and Technology Award in recognition of Gen-Probe's pioneering work in the research and development of innovative nucleic acid determination, which ensured that the blood of national blood donors did not contain HIV- 1 virus and hepatitis C virus.
The American National Science and Technology Award is the highest honor in the field of national technological innovation.
12006 FDA awarded APTIMA? The marketing license of HIV- 1 RNA quantitative reagent.
U.S. Patent No.7 1 18892 was obtained, which improved the intellectual property rights of Gen-Probe associated with the comprehensive instrument system and facilitated the determination of nucleic acid.
14, PROCLEIX approved by FDA in 2007? Tigris? With the help of the system (the first automatic molecular diagnostic instrument), the West Nile virus (WNV) in blood, organs and tissues of blood donors was screened and determined.
15 and 2008 FDA fully approved the use of PROCLEIX in TIGRIS system. ULTRIO method is used to screen HIV- 1, HCV and HBV in blood of blood donors.
16 and spent $65,438+36 million in cash to acquire Tepnel Life Sciences Company in 2009; Located in Europe, the company is rapidly emerging in the field of molecular diagnosis, especially transplantation diagnosis.
American and European patent authorities granted Gen-Probe seven patents in other fields, which expanded its intellectual property portfolio in the field of automatic nucleic acid detection reagents.
Spent $60 million in cash to acquire Prodesse, which was once a leader in molecular detection of respiratory infection diseases.
17,2011FDA-approved gene probe APTIMA? A New Molecular Detection Reagent for Detecting Cervical Cancer Virus-Human Papillomavirus Test.
18 and 20 12 FDA approved the PROGENSAPCA3 reagent.
PANTHER system approved by FDA.
Acquisition of Gen-Probe by HOLOGIC company